Viewing data from:

TORSEMIDE

ANDA

TORSEMIDE | A076110 | TEVA PHARMACEUTICALS USA INC

4 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Torsemide (2023)

Total Spending

$62.2M

Total Claims

2,730,421

Beneficiaries

675,579

Avg Cost/Unit

$0.27

Spending Trend

$38.1M(2019)→$45.6M(2020)→$52.2M(2021)→$59.0M(2022)→$62.2M(2023)

YoY Change:-2.5%

5yr CAGR:+2.7%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain13 active DMFs5 inactive

12 active API suppliers hold Drug Master Files for this ingredient.

COSMA SPATORSEMIDE 1016

DMF 155622001

COSMA SPATORSEMIDE 1024

DMF 155632001

TAPI NL BVTORSEMIDE

DMF 157382001

CAMBREX CHARLES CITY INCTORSEMIDE USP

DMF 174892004

HETERO LABS LTDTORSEMIDE

DMF 183602007

BIOINDUSTRIA LABORATORIO ITALIANO MEDICINALI SPATORSEMIDE (MOD 1) BULK SUBSTANCE

DMF 192372006

ZHEJIANG DONGDONG PHARMACEUTICAL CO LTDTORSEMIDE

DMF 215762008

APITORIA PHARMA PRIVATE LTDTORSEMIDE USP (NON-STERILE DRUG SUBSTANCE)

DMF 231742009

IPCA LABORATORIES LTDTORSEMIDE USP

DMF 237602010

JARI PHARMACEUTICAL CO LTDTORSEMIDE

DMF 274062013

MEDILUX LABORATORIES PVT LTDTORSEMIDE

DMF 357362021

MICRO LABS LTDTORSEMIDE USP

DMF 359012021

KALINTIS HEALTHCARE PRIVATE LTDTORSEMIDE USP

DMF 366642022

TEVA PHARMACEUTICAL INDUSTRIES LTDInactiveTORSEMIDE

DMF 152222001

APOTEX PHARMACHEM INDIA PVT LTDInactiveTORSEMIDE USP

DMF 184662005

CIPLA LTDInactiveTORSEMIDE USP

DMF 219542008

MICRO LABS LTD INDIAInactiveTORSEMIDE USP

DMF 246872010

JARI PHARMACEUTICAL CO LTDInactiveTORSEMIDE

DMF 262082012

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (4)

Sort:

#001 — 5MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: May 14, 2002

No patent or exclusivity listings for this strength.

#002 — 10MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: May 14, 2002

#003 — 20MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: May 14, 2002

#004 — 100MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: May 14, 2002